Invesaro

Stocks Industrials CBIH

OTC · Industrials

Cannabis Bioscience International Holdings, Inc. (CBIH)

Cannabis Bioscience International Holdings, Inc. brought in $123.6K of revenue over the twelve months to February 28, 2026, down 64.1% from a year earlier. It posted a net loss of $515.3K. At February 28, 2026 it held $90 in cash against $290.9K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on April 16, 2026.

Watch CBIH in 60 seconds
Price
$0.00
0.00% on the day · September 25, 2026
52-week range $0.00 to $0.00
Market cap
$1.2M
Revenue (last 12 months)
$123.6K
-64.1% year on year
Net margin
-416.8%

What Cannabis Bioscience International Holdings, Inc. does

Cannabis Bioscience International Holdings, Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on OTC under the ticker CBIH.

Revenue and profit by year

Revenue
FY24: $316.8K $316.8K FY24FY24: $248.8K $248.8K FY24FY25: $303K $303K FY25
Net income
FY24: -$1M -$1M FY24FY24: -$651.3K -$651.3K FY24FY25: -$548.8K -$548.8K FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$303K-$421.4K-$548.8K-$0.00n/a
2024$248.8K-$486.1K-$651.3K-$0.00n/a
2024$316.8K-$983.4K-$1M-$0.00n/a

Full financial statements: income, balance sheet and cash flow

A report was expected around September 21, 2026 and is not on file yet.

Estimated from its filing rhythm: 52 weeks after its report of September 22, 2025. Not a date the company has announced. See the report calendar

Where CBIH ranks in Industrials

Revenue$303K
#567 of 587 in Industrials · Bottom 3%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Industrials

Latest SEC filings

What Cannabis Bioscience International Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 31, 2026
  2. July 1, 2026
  3. May 21, 2026
  4. April 16, 2026
    Quarterly report 10-Q · period to February 28, 2026Revenue fell 25% to $11.2K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
  5. April 15, 2026
  6. April 14, 2026
  7. April 13, 2026
  8. March 27, 2026
  9. February 19, 2026
    Quarterly report 10-Q · period to November 30, 2025Revenue fell 28% to $53.3K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
  10. January 14, 2026

Recent insider filings (Forms 3, 4 and 144): 1, the latest on May 11, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about CBIH

What does Cannabis Bioscience International Holdings, Inc. do?

Cannabis Bioscience International Holdings, Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on OTC under the ticker CBIH.

Is Cannabis Bioscience International Holdings, Inc. profitable?

No. Over the twelve months to February 28, 2026 it reported a net loss of $515.3K on revenue of $123.6K.

How much revenue does Cannabis Bioscience International Holdings, Inc. make?

Over the twelve months to February 28, 2026 Cannabis Bioscience International Holdings, Inc. reported revenue of $123.6K. That is 64.1% less than a year earlier.

When did Cannabis Bioscience International Holdings, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on April 16, 2026. It covers the period to February 28, 2026. Its newest filing of any kind is the late annual report notice from August 31, 2026.

Similar companies

Compare CBIH with

Compare CBIH with any company

Follow CBIH

Get an email when Cannabis Bioscience International Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CBIH: get an email when it files

Where the numbers come from

Financial figures are the values Cannabis Bioscience International Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.